EXOZ Invizyne: Enterprise Value to EBITDA Ratio
eXoZymes Inc (EXOZ) possesses significant pricing power through its SimpleCell platform, which enables the synthesis of complex substances without the use of bacteria. The company has earned scientific recognition by implementing environmentally safe chemical production methods. This chart illustrates an EV/EBITDA ratio of 0.00. The enterprise currently operates pilot plants under contract, maintaining its equipment in ideal technical condition.
Comprehensive metric breakdowns and analytics for invizyne.com (EXOZ)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
- financial results and valuation multiples details:
EXOZ - Profit After Tax|Future Profit eXoZymes Inc|EXOZ - Market Cap to Earnings|Future Price to Earnings eXoZymes Inc|EXOZ - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Invizyne|EXOZ - Profit before interest, taxes and amortization|Earnings per share for the last twelve months eXoZymes|EXOZ - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months invizyne.com|EXOZ - Earnings per share increase in current year|Earnings growth forecast for next year eXoZymes Inc
Initial company analysis:Invizyne Technologies, Inc. (EXOZ)
This multiple determines the business value relative to its operating profit, accounting for debt load and tax obligations. It measures the company's ability to generate cash flow to service debt amid cost-push inflation. By analyzing the current EV/EBITDA with debt, an investor assesses the capitalization's resilience to operational risks. For eXoZymes Inc. (EXOZ), this is critical due to the lack of serial production and a reliance on grants when scaling synthesis.
Competitor analysis for eXoZymes Inc
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Haleon Group HLN|Kenvue Health (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|jyongbio.com - Enterprise Value to Operating Income Before Depreciation Ratio|LGND: EV/EBITDA Multiple|Amneal Pharmaceuticals, Inc. - Business Value to Operating Income Before Depreciation|PRGO (Perrigo Company) - EV/EBITDA Multiple|Company Value to EBITDA Alvotech Biopharmaceuticals ALVO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Liquidia Corporation (LQDA)|GLPG (glpg.com) - Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ANIP (ANI Pharmaceuticals, Inc.)|MannKind Corp (MNKD) - Company Value to EBITDA|AMPH: Enterprise Value to EBITDA Ratio|PCRX (Pacira Corp) - Enterprise Value to Operating Income Before Depreciation|ARS Pharmaceuticals (SPRY) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA theravance.com (TBPH)|Enterprise Value to EBITDA Ratio AQST|scPharma - Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio TECX (Tectonic Therapeutic, Inc.)|TNXP - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization China SXT Pharmaceuticals, Inc. SXTC|EPRX - Enterprise Value to EBITDA Ratio|BioHarvest Sciences Inc. - EV/EBITDA Multiple|Company Value to EBITDA Oramed Pharmaceuticals|enterabio.com (ENTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|HYFT - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio ABVC|CPIX: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple QNTM|Total Company Value to Operating Income Before Depreciation Ratio FibroGen Inc|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Telomir Pharma TELO|RANI: Enterprise Value to Operating Income Before Depreciation|Synergy CHC Corporation - EV/EBITDA Multiple|Rallybio Corporation (RLYB) - Enterprise Value to EBITDA Ratio|LEXX: EV/EBITDA Multiple|Company Value to EBITDA Pulmatrix Inc (PULM)|Enterprise Value to EBITDA Ratio PTHL|Enterprise Value to Operating Income Before Depreciation APM (Aptorum)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lyra Therapeutics, Inc. (LYRA)|IBO - Company Value to EBITDA|TNF Pharmaceuticals, Inc. - Enterprise Value to EBITDA Ratio|YCBD (cbdMD Inc.) - Company Value to Operating Income Before Depreciation Ratio|PRFX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio CYTO|LIPO: EV/EBITDA Multiple|optinose.com - Business Value to Operating Income Before Depreciation|PIRS (Pieris Pharmaceuticals, Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple Procaps Group|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Petros (PTPI)|QLI (Qilian International Corp) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Acelyrin, Inc. SLRN|TFFP - Enterprise Value to EBITDA Ratio
